Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Goodwill (2022 - 2024)

Neurocrine Biosciences (NBIX) has disclosed Goodwill for 1 consecutive years, with $5.8 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Goodwill changed N/A year-over-year to $5.8 million, compared with a TTM value of $5.8 million through Dec 2023, changed N/A, and an annual FY2023 reading of $5.8 million, changed N/A over the prior year.
  • Goodwill was $5.8 million for Q4 2023 at Neurocrine Biosciences.
  • Across five years, Goodwill topped out at $5.8 million in Q4 2023 and bottomed at $5.8 million in Q4 2023.